TY - JOUR
T1 - Research on the Epidemiology of SARS-CoV-2 in Essential Response Personnel (RECOVER)
T2 - Protocol for a Multisite Longitudinal Cohort Study
AU - Edwards, Laura J.
AU - Fowlkes, Ashley L.
AU - Wesley, Meredith G.
AU - Kuntz, Jennifer L.
AU - Odean, Marilyn J.
AU - Caban-Martinez, Alberto J.
AU - Dunnigan, Kayan
AU - Phillips, Andrew L.
AU - Grant, Lauren
AU - Herring, Meghan K.
AU - Groom, Holly C.
AU - Respet, Karley
AU - Beitel, Shawn
AU - Zunie, Tnelda
AU - Hegmann, Kurt
AU - Kumar, Archana
AU - Joseph, Gregory
AU - Poe, Brandon
AU - Louzado-Feliciano, Paola
AU - Smith, Michael
AU - Thiese, Matthew S.
AU - Schaefer-Solle, Natasha
AU - Yoo, Young M.
AU - Silvera, Carlos A.
AU - Lamberte, Julie Mayo
AU - Mak, Josephine
AU - McDonald, L. Clifford
AU - Stuckey, Matthew J.
AU - Kutty, Preeta
AU - Arvay, Melissa L.
AU - Yoon, Sarang K.
AU - Tyner, Harmony L.
AU - Burgess, Jefferey L.
AU - Hunt, Danielle Rentz
AU - Meece, Jennifer
AU - Gaglani, Manjusha
AU - Naleway, Allison L.
AU - Thompson, Mark G.
N1 - Funding Information:
ALN reports funding from Pfizer for a meningococcal B vaccine study unrelated to the submitted work. KTH serves at the Editor of the American College of Occupational and Environmental Medicine evidence-based practice guidelines. MST reports grants and personal fees from Reed Group and the American College of Occupational and Environmental Medicine, outside the submitted work. The other authors report no conflicts of interest.
Funding Information:
The RECOVER study is funded by the US Centers for Disease Control and Prevention (CDC). The CDC and Abt Associates made key decisions on the study design, with scientific and operational input from investigators at each of the 6 study sites. Marshfield Clinical Research Institute in Marshfield, Wisconsin advised on laboratory methods for respiratory specimens in the study, and the CDC advised on the laboratory methods for serologic specimens. All study sites use a common protocol and data collection instruments approved by their institutional review boards (IRBs), as well as standard operating procedures.
Publisher Copyright:
© 2021 The Authors
PY - 2021/12
Y1 - 2021/12
N2 - Background: Workers critical to emergency response and continuity of essential services during the COVID-19 pandemic are at a disproportionally high risk of SARS-CoV-2 infection. Prospective cohort studies are needed for enhancing the understanding of the incidence of symptomatic and asymptomatic SARS-CoV-2 infections, identifying risk factors, assessing clinical outcomes, and determining the effectiveness of vaccination. Objective: The Research on the Epidemiology of SARS-CoV-2 in Essential Response Personnel (RECOVER) prospective cohort study was designed to estimate the incidence of symptomatic and asymptomatic SARS-CoV-2 infections, examine the risk factors for infection and clinical spectrum of illness, and assess the effectiveness of vaccination among essential workers. Methods: The RECOVER multisite network was initiated in August 2020 and aims to enroll 3000 health care personnel (HCP), first responders, and other essential and frontline workers (EFWs) at 6 US locations. Data on participant demographics, medical history, and vaccination history are collected at baseline and throughout the study. Active surveillance for the symptoms of COVID-19–like illness (CLI), access of medical care, and symptom duration is performed by text messages, emails, and direct participant or medical record reports. Participants self-collect a mid-turbinate nasal swab weekly, regardless of symptoms, and 2 additional respiratory specimens at the onset of CLI. Blood is collected upon enrollment, every 3 months, approximately 28 days after a reverse transcription polymerase chain reaction (RT-PCR)–confirmed SARS-CoV-2 infection, and 14 to 28 days after a dose of any COVID-19 vaccine. From February 2021, household members of RT-PCR–confirmed participants are self-collecting mid-turbinate nasal swabs daily for 10 days. Results: The study observation period began in August 2020 and is expected to continue through spring 2022. There are 2623 actively enrolled RECOVER participants, including 280 participants who have been found to be positive for SARS-CoV-2 by RT-PCR. Enrollment is ongoing at 3 of the 6 study sites. Conclusions: Data collected through the cohort are expected to provide important public health information for essential workers at high risk for occupational exposure to SARS-CoV-2 and allow early evaluation of COVID-19 vaccine effectiveness.
AB - Background: Workers critical to emergency response and continuity of essential services during the COVID-19 pandemic are at a disproportionally high risk of SARS-CoV-2 infection. Prospective cohort studies are needed for enhancing the understanding of the incidence of symptomatic and asymptomatic SARS-CoV-2 infections, identifying risk factors, assessing clinical outcomes, and determining the effectiveness of vaccination. Objective: The Research on the Epidemiology of SARS-CoV-2 in Essential Response Personnel (RECOVER) prospective cohort study was designed to estimate the incidence of symptomatic and asymptomatic SARS-CoV-2 infections, examine the risk factors for infection and clinical spectrum of illness, and assess the effectiveness of vaccination among essential workers. Methods: The RECOVER multisite network was initiated in August 2020 and aims to enroll 3000 health care personnel (HCP), first responders, and other essential and frontline workers (EFWs) at 6 US locations. Data on participant demographics, medical history, and vaccination history are collected at baseline and throughout the study. Active surveillance for the symptoms of COVID-19–like illness (CLI), access of medical care, and symptom duration is performed by text messages, emails, and direct participant or medical record reports. Participants self-collect a mid-turbinate nasal swab weekly, regardless of symptoms, and 2 additional respiratory specimens at the onset of CLI. Blood is collected upon enrollment, every 3 months, approximately 28 days after a reverse transcription polymerase chain reaction (RT-PCR)–confirmed SARS-CoV-2 infection, and 14 to 28 days after a dose of any COVID-19 vaccine. From February 2021, household members of RT-PCR–confirmed participants are self-collecting mid-turbinate nasal swabs daily for 10 days. Results: The study observation period began in August 2020 and is expected to continue through spring 2022. There are 2623 actively enrolled RECOVER participants, including 280 participants who have been found to be positive for SARS-CoV-2 by RT-PCR. Enrollment is ongoing at 3 of the 6 study sites. Conclusions: Data collected through the cohort are expected to provide important public health information for essential workers at high risk for occupational exposure to SARS-CoV-2 and allow early evaluation of COVID-19 vaccine effectiveness.
KW - COVID-19
KW - Cohort study
KW - Essential
KW - First responder
KW - Frontline workers
KW - Health care personnel
KW - Incidence
KW - SARS-CoV-2
KW - Vaccine effectiveness
UR - http://www.scopus.com/inward/record.url?scp=85119391954&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85119391954&partnerID=8YFLogxK
U2 - 10.2196/31574
DO - 10.2196/31574
M3 - Article
AN - SCOPUS:85119391954
VL - 10
JO - JMIR Research Protocols
JF - JMIR Research Protocols
SN - 1929-0748
IS - 12
M1 - e31574
ER -